Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reed Miller

Manager, US Commercial and R&D

Washington, DC
Reed, Manager, US Commercial and R&D, got his first real job in journalism in 2000 with The Gray Sheet, then part of FDC Reports, based outside of Washington, DC, and has been covering medical technology ever since. His primary focus has been clinical trials and new product development, so he has covered innumerable FDA advisory panel meetings and Medicare coverage decisions. Mixed in to his many years with The Gray Sheet, Reed spent a year in Massachusetts with HCPro in that company’s pharma compliance editorial group, and three years as a reporter for theheart.org, when it was the best news source for cardiologists. In 2015, he’s became deputy editor of Clinica, continuing to track the bewildering and rapidly evolving universe of new medical technology, from IVDs to artificial hearts, from pre-clinical trials to commercialization. Reed has a BA in religion from the College of William & Mary and an MA in Philosophy of Religion from Boston University. He lives and works in his hometown of State College, Pennsylvania.

Latest From Reed Miller

Cardiovascular Catch-Up: TAVR Withstands Delta Virus So Far; Stereotaxis Robot Succeeds In Trial

The impact of the Delta variant of COVID-19 on procedure volumes remains a major concern for transcatheter valve makers, Abbott launches a new PFO closure device, and more highlights from the cardiovascular technology market in early October.

Cardiovascular Approvals

Device Week, 21 October 2021 – Post-Pandemic Perspectives; Good And Bad News For Medtronic

In this edition of Device Week, Medtech Insight’s Reed Miller discusses some important news from Medtronic and Marion Webb reviews the first of two feature articles on the impact of the pandemic on the medtech industry around the world.

Device Week Coronavirus COVID-19

J&J Pushes Back Launch Of Ottava Robotic Platform By Two Years

The company originally expected the first-in-human trial of the soft-tissue robotic surgery system to begin in late 2022 and reach the market by 2023, but the company now expects those trials to begin in 2024.

Robotic Surgery Clinical Trials

Medtronic Pushes Completion Of Pivotal Renal Denervation Trial To Late 2022

The company announced that results from the pivotal SPYRAL HTN-ON MED trial of its Symplicity renal denervation system will not be available until the trial completes enrollment next year. The company previously expected to be able to present favorable interim results from the trial in November.

Clinical Trials Approvals

Hologic Adds Vessel Sealing Tech By Acquiring Bolder Surgical For $160M

Colorado-based Bolder recently announced the global launch of the CoolSeal vessel sealing platform, which will complement Hologic’s obstetrical/gynecological surgery product line.

M & A Gynecology & Urology

Medtronic ‘Refreshes Brand,’ Announces New Environmental, Social, and Governance Targets

The company reported its progress in key environmental, social, and governance areas over the past year along with some new performance targets related to sustainability and inclusion. Medtronic also added a new “tagline” to its brand.

Sustainability Diversity & Inclusion
See All
UsernamePublicRestriction

Register